CLOs on the Move


 
Stay compliant with a quality management system (eQMS) designed to streamline your process, easily be used by your team, and priced differently to make controlling quality together possible, whether you are a small startup or multi-site team.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.zenqms.com
  • 40, Coulter Avenue
    Ardmore, PA USA 19003
  • Phone: 267.670.8999

Executives

Name Title Contact Details

Similar Companies

alligatortek

alligatortek is a Chicago, IL-based company in the Software and Internet sector.

KCD Software

Powerful custom 3D design to manufacturing software to facilitate woodworkers, designers, builders and renovators of cabinetry and closets.

eConnect

eConnect is an award-winning gaming & hospitality technology. POS Connect, Casino Connect & Facial Recognition.

Pricefx

Established in 2011 in Germany, Pricefx AG is a provider of full suite price management and CPQ SaaS solutions. Our suite is based on the latest in native cloud architecture and offers flexible support for the entire price management closed loop cycle which includes pricing strategy, controlling, setting and realization. Our solution is suitable for B2B and B2C clients and is able to serve a wide array of industries. The platform is also designed to meet the specific pricing challenges of commercial organizations of any size or geographical location. Pricefx`s vision is to become the leading SaaS pricing solution provider by offering an easily implemented and flexible tool that is inexpensive, risk-free and fully comprehensive. Our business model is based entirely on the satisfaction and loyalty of our customers. If we do our job, they stay, and more importantly, they tell others about us.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.